(Resetting microEnvironmental interactions in the nervous System after Chemotherapy Exposure)

CHALLENGE: Chemotherapy-induced neurotoxicities
Gradient line

Team RESCuE aims to understand the biology that underpins chemotherapy-induced neurotoxicities to address the cause, consequence and cure of these side effects.

Team Leads
Michelle Monje (Stanford Medicine) and Alison Lloyd (University College London)
Canada, Germany, Netherlands, UK, US

The idea

Using powerful tools of modern neuroscience, coupled with expertise in the cancer field, the RESCuE team aims to take an ambitious, interdisciplinary approach to address the cause, consequence and cure of chemotherapy-induced neurotoxicities in the central nervous system and peripheral nervous system.  

Focused on chemotherapy-related cognitive impairment (CRCI) and chemotherapy-induced peripheral neuropathy (CIPN) in adults and children, the team hopes to provide an unparalleled analysis of chemotherapy-induced neurotoxicities, define the biology underlying risk and generate new screening platforms for treatment development.   

The team plans to study chemotherapeutic agents with distinct mechanisms of action but similar neurotoxicities to determine the neurobiological underpinnings of CRCI and CIPN. This will allow for biomarker identification and the development of new prevention and treatment strategies for CRCI and CIPN.  

RESCuE’s approach will make use of multiple models including zebrafish, mouse and human stem cell models, in the presence and absence of tumours.  

Collaborating with and learning from people affected by cancer will be central to the team’s work. 

"We are enormously grateful to have this opportunity, and hopeful that the proposed work could change the landscape of chemotherapy-related neurotoxicities to elicit real progress in treatment and quality of life for people with cancer."